2026 U.S. 50-State + DC Telehealth Modality, Medicaid GLP-1 Coverage & Local Clinic Cost Report
By Losing Weight RX Pharmacoeconomics & Consumer Audit Desk · Verified 2026-11-11 · Open Dataset: us-50-state-telehealth-glp1-access-medicaid-matrix-2026 (10.5281/zenodo.24139340)
Across all 50 U.S. states and Washington, D.C., fewer than one-third of state Medicaid programs cover adult obesity GLP-1 medications, while local brick-and-mortar weight-loss medspas charge a median $475/month for semaglutide and $685/month for tirzepatide. Switching to licensed 503A national telehealth ($49/mo semaglutide; $99/mo tirzepatide) saves households a median $5,112 to $7,032 annually.
1. Percentile Distribution Analysis (N = 51 Audited Observations)
All distribution percentiles below are computed directly from the machine-readable CSV and Apache Parquet splits archived under 10.5281/zenodo.24139340:
| Measure | Min | P10 | Q1 (P25) | Median (P50) | Q3 (P75) | P90 | Max | Mean | IQR |
|---|---|---|---|---|---|---|---|---|---|
| Local Brick-and-Mortar MedSpa Monthly Semaglutide Median (USD) | 430.00 | 435.00 | 445.00 | 465.00 | 495.00 | 555.00 | 595.00 | 480.88 | 50.00 |
| Annual Household Savings Switching to $49/mo Online Flat Rate (USD) | 4,572.00 | 4,632.00 | 4,752.00 | 4,992.00 | 5,352.00 | 6,072.00 | 6,552.00 | 5,182.59 | 600.00 |
2. Audited Benchmark Sample (Lowest Total Annual Cost First)
| state name | state postal code | local bariatric medspa sema median usd | annual household sema savings usd | state access equity score 100 |
|---|---|---|---|---|
| Alabama | AL | 465.0 | 4992.0 | 66 |
| Alaska | AK | 525.0 | 5712.0 | 76 |
| Arizona | AZ | 450.0 | 4812.0 | 76 |
| Arkansas | AR | 440.0 | 4692.0 | 52 |
| California | CA | 575.0 | 6312.0 | 94 |
| Colorado | CO | 495.0 | 5352.0 | 76 |
| Connecticut | CT | 540.0 | 5892.0 | 94 |
| Delaware | DE | 485.0 | 5232.0 | 80 |
| District of Columbia | DC | 590.0 | 6492.0 | 94 |
| Florida | FL | 475.0 | 5112.0 | 76 |
| Georgia | GA | 460.0 | 4932.0 | 76 |
| Hawaii | HI | 560.0 | 6132.0 | 76 |
| Idaho | ID | 435.0 | 4632.0 | 66 |
| Illinois | IL | 495.0 | 5352.0 | 76 |
Inspect Full 51-Row Interactive Dataset & Download CSV →
3. Frequently Asked Pharmacoeconomic Questions
Do any U.S. states require a live video visit rather than asynchronous intake for telehealth prescriptions?
Yes. While 45 jurisdictions permit structured store-and-forward or hybrid asynchronous clinical evaluations when clinically appropriate, states such as Arkansas, Delaware, Mississippi, New Mexico, and West Virginia enforce stricter synchronous audio-video telehealth examination rules.
How do non-resident 503A sterile compounding pharmacy rules protect patients across states?
States including California, Alabama, Louisiana, and Mississippi enforce dual non-resident sterile compounding licensure and USP <797> sterility compliance checks on partner pharmacies shipping cold-chain medications to residents.